Companies
Galvani Bioelectronics
its splenic neuromodulation therapy for rheumatoid arthritis received FDA approval to progress to the randomized, controlled stage of clinical feasibility testing, alongside a new Chief Medical Officer appointment.
- Country
- United Kingdom
Investigational
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| regenerative-personalized | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Bioelectronic medicine & neuromodulation | regenerative-personalized | Medium | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.